Published in Internist (Berl) on September 01, 2015
Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria. Acta Biomater (2005) 4.22
Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res (2001) 2.29
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
[Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol (2008) 1.81
Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem (2000) 1.76
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol (2005) 1.71
Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res (1999) 1.67
[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52
CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut (2009) 1.31
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol (2010) 1.27
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol (2008) 1.02
Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression. Pancreas (2001) 0.94
Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. FEBS Lett (1996) 0.94
Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation. Oncogene (2007) 0.93
KOC is a novel molecular indicator of malignancy. Br J Cancer (2003) 0.93
Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility. Oncogene (2010) 0.92
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol (2009) 0.90
Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther (2010) 0.85
Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells. J Biol Chem (1997) 0.84
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J (2011) 0.84
Lysophosphatidic acid-depleted serum, hepatocyte growth factor and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway. Cancer Res (1994) 0.82
Subclinical ascites defines an intermediate stage between compensated and decompensated cirrhosis. Z Gastroenterol (2012) 0.82
Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport (1998) 0.82
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer (2013) 0.80
Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas. Cancer Res (1998) 0.80
Effect of galanin on gastrin and somatostatin release from the rat stomach. Life Sci (1988) 0.80
[Immunosuppressive treatment as a risk factor for the occurrence of clostridium difficile infection (CDI)]. Z Gastroenterol (2013) 0.78
[Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]. Dtsch Med Wochenschr (2007) 0.78
[Chemotherapy for colorectal carcinoma in the elderly]. Z Gastroenterol (2004) 0.78
[Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)]. Z Gastroenterol (2012) 0.78
Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013. Int J Colorectal Dis (2014) 0.77
[Prolonged course of tick-borne ulceroglandular tularemia in a 20-year-old patient in Germany--case report and review of the literature]. Dtsch Med Wochenschr (2009) 0.76
In-vivo monitoring of acute DSS-Colitis using Colonoscopy, high resolution Ultrasound and bench-top Magnetic Resonance Imaging in Mice. Eur Radiol (2015) 0.76
Effect of gastrin-releasing peptide (GRP1-27), neuromedin-C (GRP18-27), and neuromedin-B on gastrin and somatostatin secretion from the rat stomach. Z Gastroenterol (1989) 0.75
[Induced pluripotent stem cells. A new resource in modern medicine]. Internist (Berl) (2014) 0.75
[Pregnancy and inflammatory bowel disease]. Internist (Berl) (2011) 0.75
[Gastrointestinal oncology - therapy update 2008 / 2009]. Z Gastroenterol (2009) 0.75
[50 years for the ZfG]. Z Gastroenterol (2013) 0.75
[Adjuvant chemotherapy of solid tumors of the gastrointestinal tract: where is the progress?]. Internist (Berl) (2007) 0.75
[Personalized therapy of gastrointestinal cancers--possibilities and limitations]. Dtsch Med Wochenschr (2010) 0.75
[ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003]. Z Gastroenterol (2003) 0.75
[ASCO update -- highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004]. Z Gastroenterol (2004) 0.75
Integrin-mediated differentiation of a pancreatic carcinoma cell line is independent of FAK or MAPK activation levels. Pancreas (2001) 0.75
Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-kappaB independent mechanisms. Oncogene (2003) 0.75
[ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]. Z Gastroenterol (2006) 0.75
[Mechanisms of disease]. Z Gastroenterol (2005) 0.75
[Editorial]. Z Gastroenterol (2011) 0.75
[ASCO-Update 2005--Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005]. Z Gastroenterol (2005) 0.75
Atherosclerosis, aortic stenosis and sudden onset central diabetes insipidus. Exp Clin Endocrinol Diabetes (1997) 0.75
[A 40-year-old female patient with seronegative autoimmune hepatitis following a newly acquired hepatitis B infection]. Z Gastroenterol (2008) 0.75
[Certified stomach cancer centres as seen by their directors: results of a questionaire to key personnel]. Z Gastroenterol (2012) 0.75
[What can colorectal cancer centers achieve in the diagnostics and therapy of colorectal liver metastases?]. Chirurg (2014) 0.75
[Pregnancy under immunosuppression]. Internist (Berl) (2011) 0.75
Effect of met-enkephalin and met-enkephalin-Arg6-Phe7 on bombesin-like immunoreactivity (BLI), somatostatin and gastrin secretion from the perfused rat stomach. Hepatogastroenterology (1990) 0.75